AI-Powered Summary
Market Context
Top Queries
More News
Explore Prysm Tools
Related Stories
Mankind Pharma: ICRA Withdraws ₹1,500 Cr Commercial Paper Rating
Mankind Pharma Limited
January 16, 2026, 12:55 PM
Mankind Pharma Limited announced that ICRA Limited has withdrawn the credit rating for its ₹1,500 crore Commercial Paper, effective January 16, 2026. The company's other outstanding ratings, including ₹5,000 crore in Non-Convertible Debentures and ₹1,250 crore in fund-based limits, remain unchanged.
Top Queries to Ask About Mankind Pharma Limited
InstantThinking to buy or sell Mankind Pharma Limited? Ask AI before you act.
Trusted by 5,000+ users
More Details on This News
Mankind Pharma Limited has announced the withdrawal of its credit rating for Commercial Paper worth ₹1,500 crore by ICRA Limited. This withdrawal was made at the request of the Company and was effective as of January 16, 2026.
ICRA Limited's letter dated January 16, 2026, confirmed the withdrawal of the rating for the ₹1,500 crore Commercial Paper, which previously held an (ICRA) A1+ rating.
In addition to this withdrawal, Mankind Pharma's other outstanding credit ratings remain unchanged. These include an (ICRA) AA+/Stable rating for Non-Convertible Debentures amounting to ₹5,000 crore and an (ICRA)AA+ (Stable)/(ICRA)A1+ rating for long-term/short-term fund-based limits of ₹1,250 crore.
The company has stated that this information will be made available on its website, www.mankindpharma.com.
More News on Mankind Pharma Limited
Analyze Mankind Pharma Limited